ADIM
FATE icon

Alpha DNA Investment Management’s Fate Therapeutics FATE Stock Holding History

Alpha DNA Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-147,651
Closed -$703K – 185
2023
Q2 		$703K Buy
+147,651
New +$815K 0.23% 134
2023
Q1 		– Sell
-102,094
Closed -$1.03M – 165
2022
Q4 		$1.03M Buy
+102,094
New +$1.92M 0.36% 118
2021
Q2 		– Sell
-63
Closed -$4K – 287
2021
Q1 		$4K Buy
63
+16
+34% +$1.53K ﹤0.01% 406
2020
Q4 		$4K Buy
+47
New +$2.92K ﹤0.01% 392

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpha DNA Investment Management's FATE Position: Q3 2023 in Review

Alpha DNA Investment Management sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 147,651 shares — an estimated $703K sold.

Alpha DNA Investment Management first reported a position in FATE in Q4 2020 and held it in 4 quarters. The position peaked at $1.03M in Q4 2022. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Alpha DNA Investment Management reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 147,651 Fate Therapeutics shares in Q3 2023, an estimated $703K.
  • Alpha DNA Investment Management first reported a position in Fate Therapeutics in Q4 2020 and held it in 4 quarters.
  • Alpha DNA Investment Management's Fate Therapeutics position peaked at $1.03M in Q4 2022.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Alpha DNA Investment Management's 13F filing for Q3 2023, filed 7 Nov 2023.